Navigation Links
Cytopia Presentation on VDA CYT997 at AACR Conference
Date:4/15/2009

MELBOURNE, Australia, April 15 /PRNewswire/ -- Cytopia Limited (ASX: CYT) announced that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming 100th Annual Meeting of the American Association for Cancer Research, in Denver, Colorado, USA.

Dr David Segal, Principal Scientist at Cytopia, will be presenting the poster in the Late-Breaking Research: Experimental and Molecular Therapeutics 2 poster session on Tuesday, April 21, 2009 from 8:00 AM to 2:00 PM (US MDT), Hall BF, Poster Section 26, Poster Board 18.

The poster, entitled CYT997: Preclinical studies on the antivascular effects and mode of action of a Phase II vascular disrupting agent outlines extensive preclinical data for CYT997 which is currently in Phase II clinical studies. Data for CYT997 in a panel of in vitro and in vivo assays will be shown clearly demonstrating the potent antivascular and cytotoxic effects of the compound.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.

Website: www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
2. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
3. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
4. Cytopia and Other Progen Shareholders Maintain Call for Meeting
5. Cytopia Letter to Progen Shareholders
6. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
7. Strategic Diagnostics Updates Roth Conference Presentation Time
8. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
9. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
11. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only ... tumor had a mutation-conferring resistance to chemotherapy, thousands ... genomics research has focused on finding these mutations ... even from circulating tumor DNA in blood — ... oncology therapeutics. Unfortunately, however, detecting these ...
(Date:2/16/2017)... , ... February 16, 2017 , ... EIT Digital ... primarily aimed at the agricultural industry. Pilot studies are about to get under way ... IoT, Big Data and 5G innovations. The concept is expected to be transferred eventually ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):